3 assets in Bladder Mixed Adenocarcinoma

Therapeutic assets addressing Bladder Mixed Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cabozantinib Bladder Mixed Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Bladder Mixed Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Bladder Mixed Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)